Dhaliwal R, et al. - Via TODAY study on 626 youth aged 11–17 years with type 2 diabetes (T2D) duration <2 years, the researchers intended to understand the differential treatment effects on glycemia when changes in visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) are noted. With no explanation of the race-ethnicity differences in treatment effects on glycemic control, increased VAT was noted more in metformin plus rosiglitazone (M + R) in comparison to metformin and metformin plus lifestyle (M + L), in contrast to the existing reports in adults with T2D, in TODAY. No relation among treatment effects in sustaining glycemic control and differential effects on depot-specific indirect measures of adiposity were concluded.